Posted 22nd February 2021 by Nicholas Noakes
Professor Fred Kramer spoke at the recent Research & Technology Series exploring Flow Cytometry / qPCR & Digital PCR / Liquid Biopsies. During his presentation, he explained how Super Selective primers enable the simultaneous identification and quantitation of rare somatic mutations in routine multiplex PCR assays, while virtually eliminating signals from abundant closely related wild-type sequences.
Posted 28th August 2020 by Joshua Sewell
Ahead of the qPCR & Digital PCR Congress, we sat down with David Zhang to talk about his work with PCR as a diagnostic platform.
Posted 8th July 2020 by Joshua Sewell
Extracellular vesicles provide an exciting opportunity as a modality for non-invasive biomarkers, which may enable them to be used as biomarkers for tumour metastasis.
Posted 24th June 2020 by Joshua Sewell
We spoke with Dr David Guttery about his pioneering work using circulating tumour DNA to enable early detection, monitoring and therapeutic decision making for better patient outcomes in gynaecological cancers.
Posted 10th June 2020 by Liv Sewell
Bringing molecular and digital pathology closer together through a more integrative approach can lead to clear advantages for diagnostic and research workflows.
Posted 16th March 2020 by Liv Sewell
Professor Anant Madabhushi is a world-recognised, award-winning leader in computerized imaging research and translational applications, with over 160 peer-reviewed journal publications and close to 100 patents issued or pending. He is a keynote speaker at the 6th Digital Pathology & AI Congress: USA. He explains here why having patents is not enough…
Posted 9th March 2020 by Liv Sewell
Ahead of the 6th Digital Pathology & AI Congress: USA, Dr Saeed Hassanpour introduces us to the subject of his presentation: the opportunities and challenges in developing deep learning based tools for histology.
Posted 28th October 2019 by Liv Sewell
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second most common cause of cancer deaths worldwide. There is not currently a successful therapy to treat HCC in advanced stages. NASH is a primary risk factor for liver cancer.
Devanand Sarkar and his team have uncovered the molecular mechanisms leading to NASH and HCC, shedding light on the connections between obesity and cancer. He is leveraging this knowledge to develop targeted treatments for both NASH and advanced HCC. We asked him to give us a brief insight into his work ahead of his presentation at the 3rd Global NASH Congress, 2020.